Suneetha M S
(UNU-IAS)
Balakrishna
Pisupati (UNEP)
Benefit Sharing !
The Second Component of
the Third Objective!
What does the study address?
• Issues and Principles related to
benefit sharing – Access and
Ownership, Products, IP, Third
Party Entry, Benefit Sharing
• Entry points for
discussions/policy making
The Principles
• The principles are discussed under five topics in
the order of a typical scheme in a bio-
prospecting exercise:
– Defining ownership over resources and related
knowledge;
– By-products/Derivatives;
– Benefit sharing per se;
– Third Party Transfers; and
– Intellectual Property concerns.
• Sectoral Approaches and Issues
OwnershipIssues
1. Defining ownership-
1. MTAs – Transfer of possession or
ownership!
2. Ownership of sample or species!
2. Defining concepts of ownership and
knowledge
3. Transboundary issues
Derivatives/ By-Products
Issues
1. Definition of by-products and
derivatives and the scope of a product
2. Terms for unmodified by-products
3. Terms for modified by-products
Benefit Sharing
• Contexts and circumstances
• For whom is benefit sharing
warranted?
Benefit sharing—contd..
Identification of various ABS scenarios
1. Terms when original genetic resource is only used for research purposes
2. Terms when original genetic resource is commercialized
3. Terms when information on original genetic resource is commercialized
Benefit sharing—contd..
4. Terms when a natural by-product of
genetic resource is developed and
commercialized
5. Terms when a synthetic by-product of
genetic resource is developed and
commercialized
6. Terms when a by-product analogous to
the original molecule isolated is
developed and commercialized
Benefit sharing—contd..7. Terms when research product developed has
same uses as TK information accessed (direct/ unmodified use)
8. Terms when research product developed with same uses as TK information accessed is commercialized
9. Terms when research product developed has uses different from TK information accessed (indirect/ modified use)
10. Terms when research product developed with uses different from TK information accessed is commercialized
BUT!!!
Scenarios may be part of a continuum
• Reference to commercial and non-commercial activities to capitalize on the market returns of the product during various stages of value addition.
• Options to negotiate on two terms:
1) on a commitment for renegotiation of an agreement in the event of commercialization; and
2) to enter into a benefit sharing arrangement that will provide a share of benefits at every stage of value addition and market capitalization (Milestones)
• The value of the resource might increase due to
increased information, and the negotiating
power of the supplier is further strengthened.
• Hence, milestone payment streams based on
appropriate economic valuation of the product at
each stage could ensure a higher rate of return
to the supplier.
• Also be preferable to users over deterrent
upfront payments on products, whose value,
though promising, is still vague.
Benefit sharing—contd..• Identify Baseline typology of benefits (What), timing
(When), and volume (How much)
• A baseline indicates the modes and mechanisms by which benefits can be shared
Broad categories of benefits include
• Monetary benefits- upfront payments, milestone payments, funds, supply contracts/ linkages, IP benefits, etc.;
• Institutional benefits- such as venture capital funds, enterprise development;
• Capacity building- at various levels;
• Access to and transfer of technologies;
• Sharing and exchange of information
Note
• Useful to base decisions, especially with regard to monetary benefits, by devising a system to value potential benefits from the bioprospecting activity.
• This will also enable in identifying lacunae in capacities and institutions, which can be addressed in the benefit sharing scheme.
• The Role of Economic Valuation of Genetic Resources in appropriate Pricing of GRs
Third party transfer of research
results
• Defining Third party transfer
• Question of what is being transferred• Original material;
• Publications;
• Research product;
• Derivatives/ By-products;
• Intellectual Property rights (IP)
• Under what circumstances are terms for
transfer set? (commercial, research, etc)
Third party transfers contd..
• What are baseline terms for transfer ?
eg. type of resources, products, in whose
presence, authority to be intimated, type of
benefits to be shared, obligation of receiver
to honour benefit sharing agreements, and
such related terms
Intellectual Property
Issues
1. Joint Ownership of IP
1.Define joint ownership
2.Under what circumstances is it warranted?
2. Role of Certificates of Origin/ Source/
Legal Provenance
Actors in benefit sharing
• Direct ‘’actors’’- local communities ,
researchers and institutions
• Supportive/facilitating ‘’actors’’-
government, NGOs and others
Assessment of the extent to which respective
‘’actors’’ contributed to improving success
rate for a benefit sharing agreement
Therefore……..
• Benefit Sharing Guidelines are intricately
linked with Access provisions;
• There can be no single model for ABS
implementation
• Markets, Pricing, Supply and Demand
Analysis and Ownership form the basis for
a successful benefit sharing arrangement
Conclusions …contd..
What we have been focusing so far is on
economic, legal and social dimensions of ABS
But
Are we forgetting to address
the Equity Issues??
Thank You for your
Attention!